Site icon pharmaceutical daily

Global Breast Cancer Immunotherapy Market & Clinical Trials Forecast to 2028 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Breast Cancer Immunotherapy Market & Clinical Trials Forecast 2028” report has been added to ResearchAndMarkets.com’s offering.

Report Highlights:

With scientific progress, pharmaceutical research and development activities have led to the generation of novel and innovative therapies, which are creating a new era for cancer treatment. Immunotherapy is one such approach that has been around for years but only recently, researchers have been actively working on determining its therapeutic potential. Continuous innovation in breast cancer treatment has enabled the breakthrough of several novel immunotherapeutic approaches.

While conventional methods like surgery and chemotherapy have become primary therapeutic options, their long-lasting side effects and the growing possibility of developing drug resistance and cancer recurrence have called for the development of more effective treatment options. The introduction of immunotherapy, particularly immune checkpoint inhibitors has transformed the treatment for breast cancer, with immunotherapy being effective even in aggressive forms of breast cancer such as triple-negative breast cancer.

The growing demand for therapies having minimal adverse effects, improved drug development, increasing cancer incidence, and growing adoption of cancer immunotherapy above other available treatment options are key factors that are propelling the growth of the market. Moreover, approved immunotherapeutic drugs for breast cancer showing robust sales has been another factor that has resulted in a growing number of investments in the market.

Keytruda, developed by Merck has been a “blockbuster” immune checkpoint inhibitor approved for breast cancer. Since, its approval, the immunotherapy drug has only witnessed exponential growth in its annual sales. Moreover, Merck has also played strategically by introducing several combinations of this blockbuster immunotherapy drug with other treatments, creating a wider range of patient populations choosing Keytruda over other methods.

It can be said that immune checkpoint inhibitors have been a vital factor that has resulted in the growing market of breast cancer immunotherapy. Following Keytruda, several companies have launched their respective immune checkpoint blockers; however, none has had higher success than Keytruda. The improved understanding of immune evasion by cancer cells and the development of antibodies towards tumor-associated antigens have led to the enhanced growth observed in immunotherapy for breast cancer.

Additionally, moving beyond immune checkpoint inhibitors, the market of breast cancer immunotherapy is also witnessing a rise in novel treatment approaches. For instance, several pharmaceutical companies have been transforming different novel immunotherapy options for breast cancer treatment, like bispecific antibodies, oncolytic viruses, cancer vaccines, tumor-infiltrating lymphocyte therapy, and cell and gene therapies. While some of these methods have had a huge impact on hematological malignancies, pharmaceutical companies are not investigating their potential therapeutic application for breast treatment.

For the last two decades, monoclonal antibody-based therapies have brought in incredible changes in the field of breast cancer treatment, however, over time with the surge of bispecific antibodies, several clinical trials are evaluating their therapeutic potential in breast cancer. The possibility of engaging the immune system while simultaneously targeting tumor-specific antigens is expected to generate a more robust immune response. In the future, it is easily predictable that bispecific antibodies will change the treatment landscape for breast cancer immunotherapy.

Another immunotherapeutic approach that is currently gardening significant attention for researchers all over the world is tumor-infiltrating lymphocyte (TIL) therapy. Studies have shown that TILs are one of the strongest biomarkers present specifically for triple-negative breast cancer patients and could also possibly be factors resulting in a positive prognosis of the disease. Hence, as we move towards immunotherapy for breast cancer, the evaluation of tumor-infiltrating lymphocytes could be a very affordable and valuable approach that can be combined with already existing or newly emerging techniques.

Key Topics Covered:

1. Need For Breast Cancer Immunotherapy

2. Global Breast Cancer Immunotherapy Market Overview

3. Global Breast Cancer Immunotherapy Trend Analysis

4. Global Breast Cancer Immunotherapy Approved Drugs Sales, Price, Dosage and Patent Analysis

4.1 Keytruda (Pembrolizumab)

4.2 Perjeta (Pertuzumab)

4.3 Kadcyla (Ado-Trastuzumab Emtansine)

4.4 Phesgo (pertuzumab trastuzumab hyaluronidase)

4.5 Trodelvy (Sacituzumab Govitecan)

4.6 Herceptin (Trastuzumab)

4.7 Enhertu (Fam-Trastuzumab Deruxtecan)

4.8 Margenza (Margetuximab)

4.9 Tecentriq (Atezolizumab)

4.10 Avastin (Bevacizumab)

5. Global Breast Cancer Immunotherapies Clinical Trials Insight

6. Global Breast Cancer Immunotherapies Clinical Trials By Company, Country and Indication

7. Marketed Breast Cancer Immunotherapies Clinical Insight

8. Therapeutic Approaches To Breast Cancer Immunotherapy

9. New Immunotherapeutic Approaches In Trials For Breast Cancer Treatment

10. Global Breast Cancer Immunotherapy Market Dynamics

11. Competitive Landscape

11.1 Roche

11.2 Genentech

11.3 Amgen

11.4 Antibody Therapeutics

11.5 Pfizer

11.6 Merck

11.7 Novartis

11.8 Bristol-Myers Squibb

11.9 EirGenix

11.10 Prestige BioPharma

11.11 Novartis Oncology

11.12 Protheragen

11.13 Merck

11.14 LeadArtis

11.15 Mayo Clinic

11.16 Biocad

11.17 Therabest Korea

11.18 EpiThany

11.19 AstraZeneca

11.20 PACT Pharma

11.21 Xuanzhu Biopharmaceutical

11.22 Samsung Bioepis

11.23 Shanghai Novamab Biopharmaceuticals

11.24 ImmunityBio

For more information about this report visit https://www.researchandmarkets.com/r/v7e0es

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version